(Updated - June 16, 2026 9:09 AM EDT)

Craig-Hallum analyst Adam Vogel initiates coverage on PepGen Inc. (NASDAQ: PEPG) with a Buy rating and a price target of $11.00.

The analyst comments "We view PGN-EDODM1 as a high-risk but highly asymmetric myotonic dystrophy type 1 recovery story with the potential for 7-8x upside if higher-dose data validate the early clinical signal. With shares trading at below cash, little-to-no value is being assigned to PEPG’s lead DM1 program, EDO platform optionality, nor the possibility that upcoming clinical data can reframe the story. At current levels, the bar is low enough that cleaner higher-dose DM1 data could drive a meaningful recovery trade."

For an analyst ratings summary and ratings history on PepGen Inc. click here. For more ratings news on PepGen Inc. click here.

Shares of PepGen Inc. closed at $1.53 yesterday.

Analyst Comments Hot Comments Hot New Coverage New Coverage